药代动力学
医学
加药
不利影响
药理学
慢性疼痛
内科学
抗体
麻醉
神经生长因子
临床试验
临床药理学
慢性病
止痛药
生长因子
药效学
重症监护医学
作者
Yue Cheng,Xiaohong Zhu,Ye Wang,Qingqing Li,Qiao Yan,Feiyan Zeng,Shuang Li,Siyu Li,Man Chen,Ping Feng
摘要
BACKGROUND AND PURPOSE: Here we evaluated, in healthy adults, the pharmacokinetics and safety of monoclonal antibody EP9001A against nerve growth factor, which may be effective for treating chronic pain and osteoarthritis. EXPERIMENTAL APPROACH: In this phase I trial, 32 healthy adults received a single subcutaneous injection of EP9001A at doses of 1-25 mg, while 12 adults received placebo. Analysis of pharmacokinetic parameters indicated dose-proportional systemic exposure, with terminal half-life ranging from 207.47 h at 1 mg to 548.76 h at 25 mg. KEY RESULTS: All adverse events were mild and none necessitated discontinuation. The most frequent adverse events were upper respiratory tract infection, elevated liver enzymes and musculoskeletal pain. Musculoskeletal symptoms were likely attributable to nerve growth factor inhibition. These results indicate predictable pharmacokinetics and good safety of EP9001A in healthy subjects. CONCLUSIONS AND IMPLICATIONS: The dose-dependent pharmacokinetics and long half-life suggest the possibility of longer dosing intervals. Future trials should optimise dosing and evaluate long-term safety, particularly with respect to adverse musculoskeletal events arising through inhibition of nerve growth factor.
科研通智能强力驱动
Strongly Powered by AbleSci AI